Cargando…

Inhibition of GPR30 sensitized gefitinib to NSCLC cells via regulation of epithelial-mesenchymal transition

Introduction: G-protein coupled receptor 30 (GPR30) is associated with cell metastasis and drug resistance in many different cancer cells. The present study aimed to reveal the sensitivity of GPR30 to gefitinib in non-small cell lung cancer (NSCLC) cells. Methods: Cell viability and proliferation we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xiaomin, Jiang, Hongyan, Ning, Jiang, Zhang, Shufen, Cai, Ying, Wang, Liang, Yang, Jinsong, Xu, Guodong, Chen, Wei, Wang, Jianfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612443/ https://www.ncbi.nlm.nih.gov/pubmed/37890097 http://dx.doi.org/10.1177/03946320231210737

Ejemplares similares

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells
por: Wan, Xuan, et al.
Publicado: (2023)

Cisplatin resistance in gastric cancer cells is involved with GPR30‐mediated epithelial‐mesenchymal transition
por: Wang, Xiaofeng, et al.
Publicado: (2020)

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
por: Hu, Yong, et al.
Publicado: (2017)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
por: Liao, Tingting, et al.
Publicado: (2022)

Triptolide inhibits epithelial-mesenchymal transition and induces apoptosis in gefitinib-resistant lung cancer cells
por: Li, Fangqiong, et al.
Publicado: (2020)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Polarity and epithelial-mesenchymal transition of retinal pigment epithelial cells in proliferative vitreoretinopathy
por: Zou, Hui, et al.
Publicado: (2020)

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line
por: Yan, Dong, et al.
Publicado: (2015)

miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met
por: Cao, Xiaonian, et al.
Publicado: (2017)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Lentivirus-mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelial-mesenchymal transition in lung adenocarcinoma A549 cells
por: Hu, Chun-Sheng, et al.
Publicado: (2021)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Epithelial-Mesenchymal Transitions of Bile Duct Epithelial Cells in Primary Hepatolithiasis
por: Zhao, Lijin, et al.
Publicado: (2010)

Ursolic Acid Attenuates TGF-β1-Induced Epithelial–Mesenchymal Transition in NSCLC by Targeting Integrin αVβ5/MMPs Signaling
por: Ruan, Jun Shan, et al.
Publicado: (2019)

The relationship between vasculogenic mimicry and epithelial‐mesenchymal transitions
por: Liu, Qiqi, et al.
Publicado: (2016)

Study on Attenuating Angiogenesis and Epithelial–Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2
por: Jiang, Sicong, et al.
Publicado: (2018)

Matrine suppresses the migration and invasion of NSCLC cells by inhibiting PAX2-induced epithelial-mesenchymal transition
por: Yang, Jun, et al.
Publicado: (2017)

AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827
por: CHEN, JIA, et al.
Publicado: (2015)

Targeting Epithelial-to-Mesenchymal Transition in Radioresistance: Crosslinked Mechanisms and Strategies
por: Qiao, Lili, et al.
Publicado: (2022)

GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy
por: Im, Ji Hye, et al.
Publicado: (2018)

Correction: GPR119 agonist enhances gefitinib responsiveness through lactate-mediatedinhibition of autophagy
por: Im, Ji Hye, et al.
Publicado: (2022)

ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition
por: Cai, Shurui, et al.
Publicado: (2022)

Overexpression of 14-3-3ζ primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC
por: Wei, Lingyun, et al.
Publicado: (2022)

Zoledronic acid re-sensitises gefitinib-resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial-mesenchymal transition
por: Yang, Xibiao, et al.
Publicado: (2021)

Protons Sensitize Epithelial Cells to Mesenchymal Transition
por: Wang, Minli, et al.
Publicado: (2012)

Downregulation of DOCK1 sensitizes bladder cancer cells to cisplatin through preventing epithelial–mesenchymal transition
por: Chen, Da-jin, et al.
Publicado: (2016)

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
por: Guan, Shaoxing, et al.
Publicado: (2022)

MicroRNA-30e reduces cell growth and enhances drug sensitivity to gefitinib in lung carcinoma
por: Ning, Zhi-Qiang, et al.
Publicado: (2016)

The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p
por: Wei, Siliang, et al.
Publicado: (2019)

Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study
por: Dai, Lili, et al.
Publicado: (2022)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression: DUXAP10 contributes to gefitinib resistance by repressing OAS2
por: Ren, Shengnan, et al.
Publicado: (2022)

FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC
por: Zhou, Fengrui, et al.
Publicado: (2019)

MiR‐30c protects diabetic nephropathy by suppressing epithelial‐to‐mesenchymal transition in db/db mice
por: Zhao, Yanru, et al.
Publicado: (2017)

MicroRNA-30b targets Snail to impede epithelial-mesenchymal transition in pancreatic cancer stem cells
por: Xiong, Yicheng, et al.
Publicado: (2018)

MiR-30b is involved in methylglyoxal-induced epithelial-mesenchymal transition of peritoneal mesothelial cells in rats
por: Liu, Hong, et al.
Publicado: (2014)

Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases
por: Cai, Linbo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l10i3p0lo38bed7jji0qods5ef